Severe Asthma

REGISTRATION CLOSED

Severe asthma affects the female population more frequently¹ . Poor control can cause a decrease in lung capacity, which negatively impacts the quality of life of patients and the progression of the disease² . Learn more about severe asthma through our Patient Portal.

How can we facilitate the improvement of the psychological aspects of patients with severe asthma and Chronic Rhinosinusitis with Nasal Polyposis?

Emotional sphere

Available data show a prevalence of psychological comorbidities such as anxiety and depression that negatively affect asthma control. A Portuguese study found that 36% of patients with persistent asthma reported anxiety symptoms, while 12% reported depression³ .

Disease control

This comorbidity of anxiety and/or depression leads to poorer disease control^4,5 and a decrease in the quality of life of patients.

Addressing these psychological conditions in a comprehensive manner can improve disease management⁵ .

"Ellas Innovation Call – Severe Asthma"

38 solutions with a clear focus: putting the

psychological well-being of patients at the center.

Innovation thrives where empathy and science meet.

Challenges

Severe asthma poses key challenges in several areas

The challenge aims to find innovative methods that improve the psychological aspects of patients experiencing this condition, with the goal of strengthening their mental health and supporting them throughout the process.

We seek solutions that facilitate the improvement of patients' psychological aspects, leading to better control of their disease and an increase in their quality of life.

Challenge

What types of solutions can we use to improve the psychological aspects of patients with severe asthma and the consequences of the condition?

Your solution could be the answer

If you have a startup or innovative project, sign up and help us improve the quality of life of patients with severe asthma.

PARTICIPANTS

Who can participate?

Startups, research centers, universities, spin-offs, and any entity or organization, national or international, that is the exclusive owner of innovative technologies with the potential to solve challenges.

Take on the challenge and solve one or more of the proposed use cases.

They are considered medical devices and have the CE and MDR marking within the regulatory framework.

They must be protected or in the process of obtaining intellectual property rights. They must be transferable or licensable.

Have high growth potential and scalability.

*Includes having at least a TRL 6 (system or subsystem model or prototype demonstration in a relevant environment)

Cómo participar

01

Candidate Kit

Please read the candidate kit carefully and review the registration form.

02

Prepare the information

Complete the registration form and verify all information.

03

Registration form

The call is currently closed.

Find out what we offer

Growth

Explore new opportunities with the opportunity to develop your solution. GSK will work with you as a catalyst for your access to the healthcare system through seed financing.

Learning

Receive guidance and support on aspects related to research, development, and strategy within the healthcare sector. We'll also provide our expertise in regulatory, legal, and operational matters.

Connection

We facilitate access to healthcare professionals, patients, companies, and other organizations that share your solution's purpose. Collaborate with relevant industry players to solve the challenge together.

References

1. Archivos de Bronconeumología. Factors related to a higher percentage of asthma admissions in women. FRIAM study [Internet]. Spain: Carlos Melero Moreno, Antolín López-Viña ^, , Mercedes García-Salmones Martín, Carolina Cisneros Serrano, Javier Jareño Esteban, Maria Teresa Ramirez Prieto, Neumomadrid Asthma Group, 2012 [Last accessed: February 2025]. Available at: https://archbronconeumol.org/es-factores-relacionados-con-el-mayor-articulo-S0300289612000841

2. National Heart, Lung, and Blood Institute. Asthma: Causes and Triggers [Internet]. USA: NIH, 2024 [Last accessed: February 2025]. Available: https://www.nhlbi.nih.gov/es/salud/asma/causas

3. Sastre J, Crespo A, Fernandez-Sanchez A, Rial M, Plaza V, investigators of the CONCORD Study Group. Anxiety, Depression, and Asthma Control: Changes After Standardized Treatment. The Journal of Allergy and Clinical Immunology In Practice [Internet]. 2018 Nov 1;6(6):1953–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29454162

4. Chaudhuri et al., 2023

5. Plank et al., 2023

6. Stubbs et al., 2022